TL1A in Ulcerative colitis

MightyRayn panel synthesis

OmniRayn’s reading of this landscape — our interpretation, not a registry fact

The registry alone would make this look like a settled bet: multiple Phase 3 programmes running at once, including paediatric extensions, which is the posture of a mechanism people believe in. The literature complicates that considerably. The Phase 2b readout for the most advanced antibody did not separate from placebo on its primary endpoint at any dose, and development continued on secondary endpoints using a different remission instrument. Anyone reading the Phase 3 activity as vindication should read that trial report first. Note also where the mechanistic case actually sits: the distinctive argument for this target is an antifibrotic effect on extracellular matrix remodelling, which the inflammation endpoints these trials use do not directly measure.

Programs and primary evidence

Method and limits

• Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
• Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
• Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
• This page refreshes monthly (no net-new primary entity in 104 days). Mechanism classifications are our reading of the public record and may be revised.